U.S. markets open in 1 hour 40 minutes

Taro Pharmaceutical Industries Ltd. (TARO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
63.50-1.33 (-2.05%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close64.83
Open64.46
Bid61.86 x 800
Ask120.00 x 1000
Day's Range61.86 - 64.60
52 Week Range53.95 - 80.00
Volume8,827
Avg. Volume18,771
Market Cap2.408B
Beta (5Y Monthly)1.04
PE Ratio (TTM)82.25
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 10, 2018
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-19% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Taro Pharmaceutical Industries
    Weekly Stock ListSmall- and mid-cap stocks (SMID stocks) soared in 2019. They have underperformed large-caps over the past 12 months, but still may be in a better position to generate market-beating returns going forward. For one thing, SMID companies tend to focus on domestic markets, so their businesses could be poised to rebound more quickly once COVID-19 vaccines are more widely distributed and the domestic service economy recovers. As well, the prices of SMID stocks generally are lower than the prices of large-caps, as the P/E ratio on the Russell 2000 Small-Cap Index is 18x compared to a P/E of 27x for the S&P 500. Finally, the long-term record has favored SMID stocks over large-caps. From 2003-2021, the Russell 2000 Index had climbed 488%, compared to an advance of 408% for the S&P 500 index. This week's list includes stocks with market caps below $20 billion that are on the Argus BUY list and are included in our Mid-Cap Model Portfolio.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more